These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16248386)

  • 1. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer.
    Nishiyama Y; Yamamoto Y; Yokoe K; Monden T; Sasakawa Y; Tsutsui K; Satoh K; Ohkawa M
    Ann Nucl Med; 2005 Sep; 19(6):491-7. PubMed ID: 16248386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
    Mittal BR; Manohar K; Kashyap R; Bhattacharya A; Singh B; Singh G
    Hell J Nucl Med; 2011; 14(2):135-9. PubMed ID: 21761015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
    Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
    Ho CL; Chen S; Yeung DW; Cheng TK
    J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma.
    Kurli M; Reddy S; Tena LB; Pavlick AC; Finger PT
    Am J Ophthalmol; 2005 Aug; 140(2):193-9. PubMed ID: 15992753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
    Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
    Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.
    Willkomm P; Bender H; Bangard M; Decker P; Grünwald F; Biersack HJ
    J Nucl Med; 2000 Oct; 41(10):1657-63. PubMed ID: 11037995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of
    Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of 18F-FDG PET/CT in diagnosis and staging of nasopharyngeal carcinoma].
    Lin XP; Zhao C; Chen MY; Fan W; Zhang X; Zhi SF; Liang PY
    Ai Zheng; 2008 Sep; 27(9):974-8. PubMed ID: 18799039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
    Schmid RA; Hautmann H; Poellinger B; Kellner W; Moisseev A; Brinkbaeumer K; Weiss M; Hahn K; Dresel S
    Nucl Med Commun; 2003 Jan; 24(1):37-45. PubMed ID: 12501018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
    Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
    Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx.
    Yen TC; Chang JT; Ng SH; Chang YC; Chan SC; Lin KJ; Lin WJ; Fu YK; Lin CY
    J Nucl Med; 2005 Mar; 46(3):405-10. PubMed ID: 15750151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer.
    Izuishi K; Yamamoto Y; Sano T; Takebayashi R; Masaki T; Suzuki Y
    J Gastrointest Surg; 2010 Jul; 14(7):1151-8. PubMed ID: 20443074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.
    Ariake K; Motoi F; Shimomura H; Mizuma M; Maeda S; Terao C; Tatewaki Y; Ohtsuka H; Fukase K; Masuda K; Hayashi H; Takadate T; Naitoh T; Taki Y; Unno M
    J Gastrointest Surg; 2018 Feb; 22(2):279-287. PubMed ID: 29119533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET as a procedure for detecting simultaneous tumours in head and neck cancer patients.
    Nishiyama Y; Yamamoto Y; Yokoe K; Miyabe K; Ogawa T; Toyama Y; Satoh K; Ohkawa M
    Nucl Med Commun; 2005 Mar; 26(3):239-44. PubMed ID: 15722904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET/CT in pancreatic adenocarcinoma: A role at initial imaging staging?
    Wartski M; Sauvanet A
    Diagn Interv Imaging; 2019 Dec; 100(12):735-741. PubMed ID: 31402332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.